首页> 外文OA文献 >PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).

【2h】

PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).

机译：PD3-2-7：在晚期非小细胞肺癌（NSCLC）的血管内皮生长因子受体（VEGFR）抑制剂联合铂类化疗的试验中，肿瘤空化对反应评估的意义：加拿大国家癌症研究所临床试验小组（NCIC CTG）。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Laurie Scott A.; Crabb Simon; Arnold Andrew; Goss Glen; Shepherd Frances A.; Seymour Lesley;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. 93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group [J] . E.Chen, D.Jonker, M.Maclean, European Journal of Cancer Supplements . 2006,第12期

机译：93 POSTER I期每日口服AZD2171（血管内皮生长因子受体（VEGFR）的抑制剂）与奥沙利铂和5-Fu输注（mFOLFOX6）联合治疗晚期结直肠癌（CRC）的研究：美国国家癌症研究加拿大癌症研究所临床试验小组
2. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. [J] . Goodwin R, Ding K, Seymour L, Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第11期

机译：接受或不接受血管内皮生长因子受体抑制剂西地尼布化疗的晚期非小细胞肺癌患者的治疗性高血压和预后：NCIC临床试验小组研究BR24。
3. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy withn or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24 [J] . Annals of Oncology . 2010,第11期

机译：接受或不接受血管内皮生长因子受体抑制剂西地尼布化疗的晚期非小细胞肺癌患者的治疗性高血压和预后：NCIC临床试验小组研究BR24
4. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
5. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials [O] . Minghui Zhang, Hongsheng Guo, Shu Zhao, 2016

机译：表皮生长因子受体抑制剂联合化疗在晚期非小细胞肺癌中的疗效：一项随机对照试验的荟萃分析
6. P3-068: An economic analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, a randomized trial of erlotinib versus best supportive care after cisplatin based chemotherapy in advanced non-small-cell lung cancer (NSCLC) [O] . Bradbury Penelope A., Seymour Lesley, Ng Raymond, 2007

机译：P3-068：加拿大国家癌症研究所临床试验组（NCIC CTG）BR.21的经济分析，这是一项厄洛替尼与基于顺铂的化疗后晚期非小细胞肺癌（NSCLC）最佳支持治疗的随机试验

著录项

相似文献

相关主题

期刊订阅